607 results about "Multipotential stem cell" patented technology

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

The invention relates to the technical field of cell automation augmentation and culture instrument, in particular relates to an automation augmentation and culture system of induced pluripotent stem cells, which comprises a cell automation augmentation and culture system, an operation room and a control system which are mutually connected, wherein, the cell automation augmentation and culture system comprises a culture box and a culture box control room connected with the culture box; the culture box comprises at least one culture device for fixing a culture container fixed block of a culture container, a culture container cover automatic opening and closing system, a culture container automatic popping and closing system, a digital temperature system and at least one sensor; the culture box control room comprises an air flow purification and induction system and a culture box digital power system; and the operation room comprises a bar code automatic entry system, an liquid automatic replace system and a cell on-line observing system. By utilizing the system provided by the invention, a somatic cell can be automatically induced into a pluripotent stem cell, and the system can be used for stem cell research and clinical stem cell treatment.

Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt/β-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt/β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.

The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.

The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells. The invention system is useful for isolating somatic cells from tissue samples, producing iPSC lines from adult differentiated cells by reprogramming such cells, identifying the pluripotent reprogrammed adult cells among other cells, and expanding and screening the identified reprogrammed cells.

The invention provides a neural stem cell (NSC) strain. The NSC strain can be isolated from animal brain tissues from different species. Embryonic stem cells (ES), induced pluripotent stem cells and other stem cells can be differentiated into the NSC. The NSC strain is characterized by quick proliferating and stable passaging; prolonged expressing biomarker proteins of Oct4 and Sox1; high efficient being differentiated into a plurality of neurons and glial cells. The invention further provides an establishing method and an application for the NSC.

The invention provides culture platforms, cell media, and methods of differentiating pluriptent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of ER formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.

This application discloses a light-responsive hydrogel-based platform that can modulate multiple microenvironmental signals to direct the differentiation of human induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) into neuronal cells. The invention provides novel methods for directing differentiation of neural stem cells into neurons useful for treatment of degenerative diseases or disorders, including but not limited to Alzheimer's, Parkinson's, or spinal cord injury (SCI).

Methods of efficiently converting primate pluripotent stem cells to GABA neurons or cholinergic neurons, as well as applications thereof, are disclosed.

The invention provides a method for efficiently inducing multipotential stem cells, six inducible factors such as Oct4 (POU5f1), Sox2, c-Myc, Klf4, UFT1, Rex1 (ZFP42), and the like and p53 gene inhibitor are induced into the cells by utilizing a slow virus carrier, thereby the method can efficiently induce and produce the multipotential stem cells.

The present invention relates to a composition for promoting differentiation of pluripotent stem cells into cardiac muscle cells, and a method for inducing differentiation of pluripotent stem cells into cardiac muscle cells and a method for preparing cardiac muscle cells

The invention relates to a reprogrammed culture medium and a culture method of a reprogrammed induced multipotential stem cell. The reprogrammed culture medium is composed of a DMEM-F12 basal culturemedium and additive components, wherein the additive components comprise 60-180 microgram/mL of L-ascorbic acid, 5.3-74 micromole/L of hydrocortisone, 3-89 nanogram/mL of sodium selenite, 8-23 micromole/L of Optiferrin, 0.5-7.4 micromole/L of retinyl acetate, 40-60 nanogram/mL plant-derived recombinant human alkaline growth factors, 8-12 microgram/mL of IGF, 0.2-0.6 microgram/mL A-83, 2-6 micromole/L of CHIR99021 and 100-450 micromole/L of sodium butyrate. The use of the reprogrammed culture medium not only can improve the safety of clinical use, but also can improve the efficiency of adult cell reprogramming to induce the multipotential stem cell.

Human non-embryonic adult totipotent and pluripotent stem cells are isolated in a simplified serum-free and feeder cell-free process. Most remarkably, certain stem cells, and especially BLSCs, are extremely small, fail to exclude trypan blue, but are nevertheless able to proliferate from even high dilutions. Therefore, so obtained stem cells can be used to prepare true monoclonal stem cell populations, which are useful in numerous uses, including therapeutic, prophylactic, diagnostic, and research uses.

The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.

The invention discloses multipotent stem cells carrying human adult premature senility syndrome gene mutations, mesenchymal stem cells and a preparation method thereof. The method comprises the following steps: (1) taking human multipotent stem cells cultured in vitro, and mutating human adult premature senility syndrome genes WRN in the human multipotent stem cells to enable the WRN to lose functions, so as to obtain the human multipotent stem cells with the function-lost WRN; and (2) carrying out induced directional differentiation on the human multipotent stem cells with the function-lost WRN to obtain the mesenchymal stem cells with the function-lost WRN. The mesenchymal stem cells derived from the multipotent stem cells provided by the invention can be used for establishing a medicine screening platform for screening a WS treatment medicine, and providing more clues for delaying a natural senility process.

The invention relates to the technical field of biomedical engineering and particularly relates to a long-term in-vitro culture and directional differentiation system and method for a liver stem cell. The long-term in-vitro culture and directional differentiation system comprises an amplification culture medium with specific chemical components, and a differential medium with specific chemical components, wherein the amplification culture medium is used for carrying out in-vitro culture of a mouse or human liver stem cell, and the differential medium is used for carrying out induced differentiation on the mouse or human liver stem cell to form a matured liver cell. By using the long-term in-vitro culture and directional differentiation system and method, a selectively-amplified liver stem cell in mother cells of the liver can be obtained from a mouse embryonic liver tissue or through human multipotential stem cell differentiation, the liver stem cell can be cultured for more than 20 generations under such a condition, and the stable molecular phenotype of the liver stem cell is maintained. By using the long-term in-vitro culture and directional differentiation system and method, the cultured mouse or human liver stem cell can be further subjected to induced differentiation to form the matured liver cell with functions of secreting albumin, metabolizing urea and the like.

In the context of a stem cell-based therapy in which differentiated cells are derived from pluripotent stem cells, this application discloses approaches for eliminating residual pluripotent stem cells that may remain in a batch of differentiated progeny cells. This advantageously prevents the formation of teratoma tumors when the differentiated cells are eventually used for the therapy. This can be accomplished by exposing the batch of differentiated progeny cells and the residual pluripotent stem cells to an alternating electric field for a period of time. The frequency and field strength of the alternating electric field are such that the pluripotent stem cells die off as a result of exposure to the alternating electric fields, while the differentiated cells remain substantially unharmed. This results in a purified batch of differentiated progeny cells that is rendered safe for use in the stem cell-based therapy.